Astellas remains confident in fezolinetant despite FDA delay

21 February 2023

Japanese drugmaker Astellas (TSE: 4503) closed Monday’s trading 2% lower following some news on fezolinetant, its investigational agent for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

The US Food and Drug Administration (FDA) has notified the company that it is extending the original priority review Prescription Drug User Fee Act (PDUFA) goal date for the oral, NK3 receptor antagonist by three months, to May 22, 2023, to allow more time for the agency to complete its review.

Ahsan Arozullah, senior vice president and head of Development Therapeutic Areas, Astellas, said: “We remain confident in the clinical profile of fezolinetant and the potential benefits it could bring to women experiencing moderate to severe VMS due to menopause, and we will continue to work with the FDA on its review of the NDA for fezolinetant.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK